EU Stoxx 50 May Fall Despite Approval of Moderna Covid-19 Vaccine
Europe’s benchmark EU Stoxx 50 index may lose ground in the coming days despite the regulatory approval of Moderna’s Covid-19 vaccine as price runs into key resistance.
Related Articles
Stocks Cheer Moderna’s Vaccine News, Dollar Mixed
Global investor sentiments are boosted by more good news on coronavirus vaccines. Moderna said it’s vaccine was 94.5% effective in preventing COVID-19, based on interim…
DAX 30, EU Stoxx 50 May Rise as Investors Await Vaccine Approval
The benchmark DAX 30 and EU Stoxx 50 index may continue to push higher in the near term. However, the elongated wait for vaccine approval…
Fan Tokens, Real world use cases for NFTs, Gamification, and 2021 Price projection
[ad_1] What is Chiliz’s (CHZ) Uniqueness? Major advantages/features Sports fans only support their teams by viewing their favorite team’s play and buying their merch, making…
Executives from China’s Largest Bitcoin Mining Firms Speak About Regulatory Crackdown – Regulation Bitcoin News
[ad_1] During the course of the week, the cryptocurrency community has been focused on China and the country’s Financial Stability Board detailing that it aims…
EU Stoxx 50 Index at Risk as Europe Tightens Covid-19 Restrictions
Europe’s benchmark EU Stoxx 50 index is at risk of reversing lower as a record increase in coronavirus infections threatens to upend the Euro-zone’s economic…
Responses